{"nctId":"NCT02352103","briefTitle":"Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery","startDateStruct":{"date":"2015-01"},"conditions":["Urinary Incontinence"],"count":120,"armGroups":[{"label":"Control arm","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Vattikuti Urology Institute radical prostatectomy","Device: da Vinci Surgical System"]},{"label":"Treatment arm","type":"EXPERIMENTAL","interventionNames":["Procedure: Retzius sparing radical prostatectomy","Device: da Vinci Surgical System"]}],"interventions":[{"name":"Retzius sparing radical prostatectomy","otherNames":[]},{"name":"Vattikuti Urology Institute radical prostatectomy","otherNames":[]},{"name":"da Vinci Surgical System","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients with newly diagnosed prostate cancer undergoing robotic-assisted radical prostatectomy at the Vattikuti Urology Institute (performed by single surgeon, MM) as the primary treatment modality\n* Be able to read and speak English and be able to provide written informed consent\n\nExclusion Criteria:\n\n* patients with high risk prostate cancer,defined as a biopsy Gleason score ≥8 and/or a pre-operative prostate specific antigen value ≥20 ng/ml.\n* evidence of clinical nodal involvement (cN1) or metastatic disease (M1)\n* patients participating in a competing study\n* patients with pre-operative urinary incontinence.","healthyVolunteers":false,"sex":"MALE","minimumAge":"40 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Urinary Continence Recovery","description":"24-hour pad weights","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Urinary Continence Recovery","description":"0 pad per day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Peri and Postoperative Complications","description":"Clavien-Dindo complications","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Regained Potency Postoperatively (as Measured by Sexual Health Inventory for Men (SHIM) Score of 17 or Greater)","description":"SHIM ranges from 0-25 with higher scores indicating better sexual function; a score of \\>=22 is normal and \\>=17 is considered mild ED","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Had Biochemical Recurrence (Post-operative Prostate-Specific Antigen (PSA) Value >=0.2 ng/ml)","description":"Patients without biochemical evidence of disease recurrence (i.e. postop PSA \\>=0.2 ng/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Post-operative Urinary Function and Urinary Function-related Quality of Life","description":"International Prostatic Symptom Score (continuous score from 0-35, higher scores indicating worse urinary function)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients Who Regained Urinary Continence Postoperatively","description":"0 pad per day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Post-operative Urinary Function and Urinary Function-related Quality of Life","description":"MSKCC (Memorial Sloan Kettering Cancer Center) STAR questionnaire (symptom tracking and reporting). Score ranges from 0-25, with higher scores indicating better urinary function","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":60},"commonTop":["Acute urinary retention","Urinary tract infection","Small Bowel obstruction"]}}}